Model No.: CAS. 417716-92-8
Packaging: 10g 100g 1kg
Productivity: 100 kg/month
Place of Origin: China
Supply Ability: 50kg
Certificate: ISO 9001, GMP
Appearance White powder
Molecular weight 426.85
Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).
It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4.
Lenvatinib is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer, that can no longer be treated with radioactive iodine.
Lenvatinib is used along with another medicine, everolimus, to treat advanced RCC, a type of kidney cancer, after one course of treatment with another anti-cancer medicine.
Shandong Chenyi Environmental Protection Technology Co.,Ltd
Contact Person: Jerry
Address: No.215 Beiyuan Main street,tianqiao District,Jinan,Shandong